- Home
- REFI vs PRQR Comparison
REFI vs PRQR Comparison
Compare REFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- PRQR
- Stock Information
- Founded
- REFI 2021
- PRQR 2012
- Country
- REFI United States
- PRQR Netherlands
- Employees
- REFI N/A
- PRQR N/A
- Industry
- REFI Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- PRQR Health Care
- Exchange
- REFI Nasdaq
- PRQR Nasdaq
- Market Cap
- REFI 314.2M
- PRQR 309.5M
- IPO Year
- REFI 2021
- PRQR 2014
- Fundamental
- Price
- REFI $15.41
- PRQR $1.63
- Analyst Decision
- REFI Strong Buy
- PRQR Strong Buy
- Analyst Count
- REFI 3
- PRQR 6
- Target Price
- REFI $20.00
- PRQR $8.50
- AVG Volume (30 Days)
- REFI 138.7K
- PRQR 626.3K
- Earning Date
- REFI 03-12-2025
- PRQR 03-13-2025
- Dividend Yield
- REFI 13.33%
- PRQR N/A
- EPS Growth
- REFI N/A
- PRQR N/A
- EPS
- REFI 1.88
- PRQR N/A
- Revenue
- REFI $55,534,183.00
- PRQR $20,235,014.00
- Revenue This Year
- REFI $20.42
- PRQR $39.44
- Revenue Next Year
- REFI N/A
- PRQR N/A
- P/E Ratio
- REFI $8.22
- PRQR N/A
- Revenue Growth
- REFI N/A
- PRQR 196.41
- 52 Week Low
- REFI $14.82
- PRQR $1.59
- 52 Week High
- REFI $16.47
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- REFI 40.85
- PRQR 28.26
- Support Level
- REFI $15.32
- PRQR $1.78
- Resistance Level
- REFI $15.67
- PRQR $1.87
- Average True Range (ATR)
- REFI 0.29
- PRQR 0.10
- MACD
- REFI -0.05
- PRQR -0.02
- Stochastic Oscillator
- REFI 29.57
- PRQR 10.53
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.